Multicenter, Open-label, Parallel Clinical Investigation of the Safety and Efficacy of Advagraf (Extended Release Tacrolimus) vs. Prograf (Tacrolimus) in de Novo Kidney Recipients 1 Month After Kidney Transplantation

Trial Profile

Multicenter, Open-label, Parallel Clinical Investigation of the Safety and Efficacy of Advagraf (Extended Release Tacrolimus) vs. Prograf (Tacrolimus) in de Novo Kidney Recipients 1 Month After Kidney Transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2013

At a glance

  • Drugs Tacrolimus (Primary) ; Corticosteroid; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms AdProCISE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 09 Jan 2013 New trial record
    • 01 Jun 2012 Secondary endpoint 'Biopsy-proven-acute-transplant-rejection' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top